Between 1994 and 2002, 31 patients underwent the Ross procedure by a single surgeon. The mean age was 42 years (24-61), 87% were male and 61% were in New York Heart Association (NYHA) class III-IV. Pure aortic stenosis (AS) was present in 32% of patients, pure aortic regurgitation (AR) in 22% and mixed disease in the rest. The aortic valve was bicuspid in 93.5% of the patients. Autograft implantation was by full root replacement in all cases. Concomitant cardiac surgical procedures were carried out in 10/31 (32%). All patients had at least annual clinical and echocardiographic follow-ups. There was one early death (3%). Overall patient survival was 92.7% at 1 year and 86.1% at 5 years. Twenty-eight (96.55%) were in NYHA class I. Echocardiographic follow-up revealed none to trivial AR in 24/29 (82.75%) and mild AR in 4/29 (13.7%). There was no autograft re-operation before 5 years. The mean gradient across the autograft was low (< 4 mm Hg). There were no incidences of endocarditis or thromboembolism. None of the patients required anticoagulation. Our early experience with the Ross procedure has shown good results in relation to early and midterm morbidity, mortality, autograft, and homograft function.